Anthem Biosciences Limited — Investor Meet, 09-02-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Anthem Biosciences reported 9M FY26 consolidated revenue of Rs. 1,513 crore and PAT of Rs. 402 crore, with Q3 revenue at Rs. 423 crore. EBITDA margins improved to 41.5% for 9M due to backward integration, expecting 20%+ margin growth for FY26. Management projects mid-teens revenue growth for FY26 despite Q3 slowdown from destocking. The pipeline remains robust with 130-140 early-phase molecules and 6 in Phase 3. Capacity expansion is underway for Unit-4 and existing units, supporting future growth in peptides and biosimilars. The company is confident in its long-term trajectory and technology focus.